Breast fibrocystic change, proliferative type

Summary

Breast fibrocystic change, proliferative type (MONDO:0002585) is a disease and 1 clinical trial. Top therapeutic interventions include sulfur hexafluoride. A subtype of breast fibrocystic disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	breast fibrocystic change, proliferative type
Mondo ID	MONDO:0002585
DOID	DOID:3274
NCIT	C6940
UMLS	C1332629
MedGen	231967
Is cancer (heuristic)	no

Also known as: benign proliferative breast disease · breast fibrocystic change, proliferative type · proliferative breast disease · proliferative breast lesion · proliferative fibrocystic change · proliferative type fibrocystic change of breast · proliferative type fibrocystic change of the breast

Disease family

This is a subtype of breast fibrocystic disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › breast disorder › breast fibrocystic disease › breast fibrocystic change, proliferative type

Related subtypes (1): non-proliferative fibrocystic change of the breast

Subtypes (1): sclerosing adenosis of breast

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03954015	EARLY_PHASE1	COMPLETED	Comparison of Three Methods for Early Detection of Breast Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
SULFUR HEXAFLUORIDE	4	1